| Patents for A61K 49 - Preparations for testing in vivo (35,376) |
|---|
| 02/26/2003 | EP1284653A2 Infrared thermography and methods of use |
| 02/26/2003 | EP1019423B1 Method for producing a pentopyranosyl nucleoside |
| 02/26/2003 | EP0832068B1 Stable reagents for the preparation of radiopharmaceuticals |
| 02/26/2003 | EP0799055B1 Selective and non-invasive visualization or treatment of vasculature |
| 02/26/2003 | EP0436717B1 System for use in a method of therapeutic or diagnostic treatment |
| 02/26/2003 | CN1399563A Method for early prediction of onset of invasive cancer |
| 02/26/2003 | CN1399559A Micro-cluster liquids and methods of making and using them |
| 02/26/2003 | CN1399548A Composition for treatment of external secretion disorders |
| 02/26/2003 | CN1398640A Biodegradable microcapsulated ultrasonic contrast medium and its prepn process |
| 02/26/2003 | CN1102045C Novel compositions containing lipids and stabilizing agent |
| 02/25/2003 | US6525862 Methods and apparatus for optical imaging |
| 02/25/2003 | US6525102 Increasing storage stability of interleukin-2 by incorporating free base form arginine and succinic acid |
| 02/25/2003 | US6525080 Thiazoline acid derivatives |
| 02/25/2003 | US6524802 Methods of detecting growth differentiation factor-14 |
| 02/25/2003 | US6524553 A compound, comprising: a targeting moiety and a chelator, wherein the targeting moiety is bound to the chelator, is a qinolone nonpeptide, and binds to a receptor that is upregulated during angiogenesis |
| 02/25/2003 | US6524552 Contrast agents |
| 02/25/2003 | US6523356 Meted hyperpolarized noble gas dispensing methods and associated devices |
| 02/25/2003 | CA2085525C Long lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof |
| 02/20/2003 | WO2003014383A2 Phenotypic effects of ubiquinone deficiencies and methods of screening thereof |
| 02/20/2003 | WO2003014380A2 Microoroganisms and cells for diagnosis and therapy of tumors |
| 02/20/2003 | WO2003014157A2 Peptides conjugates, their derivatives with metal complexes and use thereof for magnetic resonance imaging (mri) |
| 02/20/2003 | WO2003014121A1 Compounds, derivatives, compositions, preparation and uses |
| 02/20/2003 | WO2003013617A2 Conjugates of macrocyclic metal complexes with biomolecules and the utilization thereof for producing agents for use in nmr diagnosis and radiodiagnosis and radiotherapy |
| 02/20/2003 | WO2003013616A1 Ionic and non-ionic radiographic contrast agents for use in combined x-ray and nuclear magnetic resonance diagnostics |
| 02/20/2003 | WO2003013587A1 Compositions for vascular occlusion |
| 02/20/2003 | WO2003013346A2 Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent |
| 02/20/2003 | WO2002096516A8 Use of compositions comprising cyclooxygenase-2 selective inhibitors in combination with radiation for inhibition or prevention of cardiovascular disease |
| 02/20/2003 | WO2002085325A3 Production and use of a suspension composition comprising an ultrasound contrast medium |
| 02/20/2003 | WO2002028441A9 Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits |
| 02/20/2003 | WO2002026193A9 Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas |
| 02/20/2003 | US20030037344 Method for evaluating the ability of a compound to inhibit neurotoxicity |
| 02/20/2003 | US20030036729 Vascular catheter having low-profile distal end |
| 02/20/2003 | US20030036697 Hollow microspheres with controlled fragility for medical use |
| 02/20/2003 | US20030036642 Platelet derived growth factor (PDGF) nucleic acid ligand complexes |
| 02/20/2003 | US20030036538 Are designed to produce both Type 1 and Type 2 phototherapeutic effect at once using dual wavelength light source that will produce singlet oxygen and free radicals at the lesion of interest. |
| 02/20/2003 | US20030035773 Diagnosis of rheumatic diseases |
| 02/20/2003 | CA2810339A1 Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia |
| 02/20/2003 | CA2456565A1 Phenotypic effects of ubiquinone deficiencies and methods of screening thereof |
| 02/20/2003 | CA2453214A1 Conjugates of macrocyclic metal complexes with biomolecules and the utilization thereof for producing agents for use in nmr diagnosis and radiodiagnosis and radiotherapy |
| 02/20/2003 | CA2452478A1 Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent |
| 02/19/2003 | EP1284146A1 Liposomes containing hydrophobic iodo compound |
| 02/19/2003 | EP1284123A1 Apparatus for marking tissue |
| 02/19/2003 | EP1283886A2 Intracellular signaling proteins |
| 02/19/2003 | EP1283873A2 Site-selective acyl transfer |
| 02/19/2003 | EP1283872A2 Catalytically active peptides |
| 02/19/2003 | EP1283842A1 Radiopharmaceutical products suitable for the selective labeling of lymphocytes, and their preparation |
| 02/19/2003 | EP1283729A2 Tc and re carbonyl complexes for pertechnetate and perrhenate |
| 02/19/2003 | EP1283728A2 Contrast agents |
| 02/19/2003 | EP0950065B1 Peptide as diagnostic and therapeutic agent for autoimmune diseases |
| 02/19/2003 | EP0729363B1 Boron-containing hormone analogs and methods of their use in imaging or killing cells having hormone receptors |
| 02/19/2003 | CN1397348A Novel target compsn. for diagnosis and treatment |
| 02/19/2003 | CN1397347A Marmem plug for microangium |
| 02/18/2003 | US6521652 Thiazoline acid derivatives |
| 02/18/2003 | US6521604 Compounds containing boron for energy-filtering transmission electron microscopy and for boron neutron-capture therapy |
| 02/18/2003 | US6521248 Cavitation; reduced pressure; oxygenated water |
| 02/18/2003 | US6521211 Methods of imaging and treatment with targeted compositions |
| 02/18/2003 | US6521210 Diagnosing a malignancy in in situ tissue. |
| 02/18/2003 | US6521209 Xanthene dyes complexed to magnetic resonance image intensifiers administered for medical diagnosis of cells, tissues or microorganism; luminescence |
| 02/13/2003 | WO2003012724A1 System and method for quantitative assessment of joint diseases and the change over time of joint diseases |
| 02/13/2003 | WO2003012072A2 Monoclonal antibodies to activated erbb family members and methods of use thereof |
| 02/13/2003 | WO2003012006A1 Colloidal nanocrystals with high photoluminescence quantum yields and methods of preparing the same |
| 02/13/2003 | WO2003011618A1 Nonskid device for the wheels of vehicles |
| 02/13/2003 | WO2003011459A1 Method for producing pharmaceutical preparations |
| 02/13/2003 | WO2003011345A1 Lipid constructs as therapeutic and imaging agents |
| 02/13/2003 | WO2003011342A2 Targeted polymeric delivery systems |
| 02/13/2003 | WO2003011326A1 Use of long pentraxin ptx3 for treating female infertility |
| 02/13/2003 | WO2003011251A1 Pulmonary formulation |
| 02/13/2003 | WO2003011220A2 Animal model for fatty acid amide-related neurobehaviors |
| 02/13/2003 | WO2003011215A2 Method and system to determine revised dosage |
| 02/13/2003 | WO2003011115A2 Peptide-based multimeric targeted contrast agents |
| 02/13/2003 | WO2003011113A2 Systems and methods for targeted magnetic resonance imaging of the vascular system |
| 02/13/2003 | WO2003011106A2 Internal image antibodies for optical imaging and therapy |
| 02/13/2003 | WO2003011051A1 Process for preparing concentrate thickener compositions |
| 02/13/2003 | WO2003011020A1 Imaging marker transgenes |
| 02/13/2003 | WO2003011019A2 Lethal mouse model for testing of pharmaceuticals and vaccines against neospororis |
| 02/13/2003 | WO2002078638A3 Morpholino imaging and therapy |
| 02/13/2003 | WO2002072551A3 A non-traumatic model for neurogenic pain |
| 02/13/2003 | WO2002067761A3 Labeled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable plaque |
| 02/13/2003 | WO2002062810A3 Linkable sialyl lewis x analogs |
| 02/13/2003 | US20030033621 Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease |
| 02/13/2003 | US20030033616 Imaging marker transgenes |
| 02/13/2003 | US20030032964 Vertebroplasty bone cement |
| 02/13/2003 | US20030032879 Microbubble formation using ultrasound |
| 02/13/2003 | US20030032791 Nucleotide sequences coding polypeptide for use in the treatment of metabolic, reproductive and eating disorders |
| 02/13/2003 | US20030031629 For use in diagnostic ultrasonic imaging |
| 02/13/2003 | US20030031628 Imaging infection using fluorescent protein as a marker |
| 02/13/2003 | US20030031627 For diagnosis and therapy |
| 02/13/2003 | US20030031626 Pharmaceutical preparation present as a dispersion, particles that are present in dispersion have a charge distribution, and particles that are present in dispersion are separated with the aid of ion exchangers or electrophoretic separation |
| 02/13/2003 | CA2455856A1 Targeted polymeric delivery systems |
| 02/13/2003 | CA2455638A1 Peptide-based multimeric targeted contrast agents |
| 02/13/2003 | CA2455598A1 Lipid constructs as therapeutic and imaging agents |
| 02/13/2003 | CA2455555A1 Animal model for fatty acid amide-related neurobehaviors |
| 02/13/2003 | CA2455210A1 Systems and methods for targeted magnetic resonance imaging of the vascular system |
| 02/13/2003 | CA2454421A1 Use of long pentraxin ptx3 for treating female infertility |
| 02/13/2003 | CA2454066A1 Pulmonary formulation |
| 02/13/2003 | CA2452547A1 System and method for quantitative assessment of joint diseases and the change over time of joint diseases |
| 02/12/2003 | EP1283060A1 Preparations for diagnosing infection with helicobacter pylori |
| 02/12/2003 | EP1282448A1 Heterobifunctional cross-linking agent conjugate substituted by an immunomodulator and cell recognition unit |
| 02/12/2003 | EP1075284B1 The use of a vital dye for facilitating surgical procedures for vitreo-retinal surgery |
| 02/12/2003 | EP0637246B1 Use of modified c-reactive protein for the preparation of a medicament for the treatment of cancer |